We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aldeyra Therapeutics Inc | NASDAQ:ALDX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.26 | 6.60% | 4.20 | 3.91 | 4.31 | 4.295 | 3.96 | 3.96 | 539,277 | 21:02:01 |
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the following healthcare investor conferences in November:
Live audio webcasts of these presentations can be accessed on the Investor Relations section of the Aldeyra Therapeutics website at https://ir.aldeyra.com. Replays will be available following the live events and will be archived on the website for 90 days.
About Aldeyra Therapeutics Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and SjÃgren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191112005614/en/
Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300 ALDX@investorrelations.com
1 Year Aldeyra Therapeutics Chart |
1 Month Aldeyra Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions